53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
Risk scores are used throughout medical care to guide treatments, allocate resources, and control outbreaksof disease. Though valuable, most risk scores are limited by their basis in aging datasets and their use withpatients in single, time-constrained consultations. Mobile health could collect longitudinal or even continuousdata on patient health. Automated, dynamic, and real-time risk profiles could trigger earlier interventions, improveclinical outcomes, guide resource distribution, and preempt outbreaks.
Dynamic risk profiles hold enormouspotential for global health, and smartphones are now uniquely equipped and positioned to unlock that potential.We identify cough, an information-rich and readily monitored syndrome, as the symptom that will pioneer ’smartrisk profiling’ systems, prove their value in alleviating the global burden of respiratory disease, and usher in anew era of proactive mobile health.
